
Clofarabine (CLO), a purine nucleoside analog with promising efficacy in acute myeloid leukemia (AML), inhibits the ribonucleotidereductase, p53R2. We have shown that p53R2 mRNA is up-regulated by decitabine (DEC), another drug with promising activity in AML. We developed a pharmacodynamic model to characterize the interaction between CLO and DEC on an AML cell line and down-regulated p53R2 protein to understand its role. These results confirm a role for p53R2 in both CLO and DEC mechanism of action, demonstrate synergism between these two drugs in this AML model and support the use of this combination in a future clinical trial.
Adenine Nucleotides, Cell Survival, Blotting, Western, Cell Cycle Proteins, Drug Synergism, Decitabine, Cell Line, Tumor, Protein Biosynthesis, Ribonucleotide Reductases, Azacitidine, Humans, Arabinonucleosides, Clofarabine
Adenine Nucleotides, Cell Survival, Blotting, Western, Cell Cycle Proteins, Drug Synergism, Decitabine, Cell Line, Tumor, Protein Biosynthesis, Ribonucleotide Reductases, Azacitidine, Humans, Arabinonucleosides, Clofarabine
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 5 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
